The strong underlying sales growth and raised guidance are positive for the stock, but the large amlitelimab impairment and pipeline discontinuation introduce uncertainty. Monitor the venglustat FDA decision (target date Nov 25, 2026) and upcoming dupixent LSC data for further pipeline catalysts. The revenue beat and guidance hike support near-term upside, but the impairment overhang may cap gains.
Drugs in focus
SNY drug pipeline →MYQORZO
▲ Bullish Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
- Next catalyst
- None dated
What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.
- ◆ Redemplo 6/10 Approved (US, FCS); Phase 3 (severe hypertriglyceridemia) ongoing; EU under review Named in filing
- ◆ venglustat 5/10 Filed/PDUFA for Gaucher type 3 (NDA under FDA priority review); Phase 3 ongoing in Fabry disease; Phase 3 GM2 (Tay-Sachs Named in filing
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion) Named in filing
- ● Nexviazyme 4/10 Approved Named in filing
- ● ALTUVIIIO 3/10 Approved (US) Named in filing
- 19 more · All SNY drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $42.89entry
- T+1 · 4mo ago +0.44%α −0.26% · $43.08
- T+5 · 3mo ago 0.00%α −3.62% · $42.89
- T+20 · 3mo ago +4.55%α +0.58% · $44.84
- T+60 · 25d ago −3.01%α −5.47% · $41.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sanofi reported H1 2026 net sales of €22,106M (+11.1% reported, +15.7% CER), driven by Dupixent (+34.4% CER) and new launches. Business EPS rose 17.1% to €3.97, and guidance was raised to ~10% CER sales growth for FY2026, with Business EPS growing slightly faster. However, IFRS net income fell 66.3% to €1,957M, largely due to a €1,031M impairment (€952M for discontinued amlitelimab) and the prior-year Opella divestiture gain. The underlying business performance is strong, but the pipeline setback and elevated restructuring costs temper the outlook.
Key Facts
- H1 2026 net sales: €22,106M, +11.1% reported, +15.7% CER vs H1 2025
- Business EPS: €3.97, +17.1% vs €3.39 in H1 2025
- IFRS net income attributable to equity holders: €1,957M, down from €5,812M (H1 2025 included €2,693M Opella gain)
- Dupixent sales: €9,324M, +27.5% reported, +34.4% CER
- €1,031M impairment of intangible assets, primarily €952M for amlitelimab (pipeline discontinuation)
- Restructuring costs: €563M, up from €430M in H1 2025
- Net debt: €15,513M, gearing 22.3% vs 15.4% at Dec 2025
- Free cash flow: €3,724M, up from €2,458M in H1 2025
- Completed acquisition of Dynavax for ~$2.2B, including HEPLISAV-B and shingles vaccine candidate
- FY2026 guidance raised: net sales growth ~10% CER, Business EPS growing slightly faster
Financial Impact
Underlying business net income up 14.8% to €4,765M, but IFRS net income down 66.3% due to impairment and prior-year gain. FY2026 guidance raised.
Risk Factors
- Amlitelimab discontinuation and pipeline setbacks in atopic dermatitis/COPD may raise questions about R&D productivity
- Net debt increased sharply, and gearing rose to 22.3%, potentially limiting flexibility for further M&A
- Restructuring costs remain elevated, and currency headwinds (-4.6% on sales) persist
- Competitive pressure on Dupixent (new entries) and vaccines (declining COVID/influenza sales)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-050803 |
| Exhibit: exhibit992-2026halfyearman.htm | 0001628280-26-050803 |
| Document: sny-20260630.htm | 0001628280-26-050803 |
Track record
15 reports on SNY
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +7.69% at T+60 after the Aug 17, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $47.47 to $48.43 Now $48.39 +1.94% ▲ +2.02% +2.94% vs SPY
- Oct 30, 202617d ago 6-K Bullish 6/10 Entry $44.34 to $47.04 Now $48.39 +9.13% ▲ +6.09% +8.79% vs SPY
- Oct 26, 202621d ago SC 13G/A Neutral 2/10 Entry $41.89 to $45.33 Now $48.39 +15.52% ▲ +8.21% +10.20% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $41.79 to $44.34 Now $48.39 +15.79% ▲ +6.10% +7.36% vs SPY
- Oct 1, 20266w ago 6-K Mixed 5/10 Entry $40.67 to $40.23 Now $48.39 +18.98% ▼ −1.08% −2.38% vs SPY
- Sep 17, 20268w ago 6-K Neutral 4/10 Entry $43.14 to $40.94 Now $48.39 +12.17% ▼ −5.10% −5.95% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $44.37 to $42.85 Now $48.39 +9.06% ▼ −3.43% −3.51% vs SPY
- Aug 17, 202613w ago Court Ruling Bullish 4/10 Entry $44.97 to $46.02 Now $48.39 +7.61% ▲ +2.33% +2.54% vs SPY
- Aug 12, 202613w ago Court Ruling Neutral 2/10 Entry $43.78 to $45.15 Now $48.39 +10.53% ▲ +3.13% +5.09% vs SPY
- Jul 31, 202615w ago Court Ruling Bullish 5/10 Entry $42.95 to $43.48 Now $48.39 +12.67% ▲ +1.23% −0.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers